Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data
IntroductionAdvanced papillary thyroid cancer (PTC) has a poor prognosis, 60~70% of which become radio iodine refractory (RAI-R), but the molecular markers that assess PTC progress to advanced PTC remain unclear. Meanwhile, current targeted therapies are badly effective due to drug resistance and ad...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.969914/full |
| _version_ | 1811215306136223744 |
|---|---|
| author | Hui He Hui He Hui He Shan Cong Yu Wang Yu Wang Qinghai Ji Qinghai Ji Weiyan Liu Ning Qu Ning Qu |
| author_facet | Hui He Hui He Hui He Shan Cong Yu Wang Yu Wang Qinghai Ji Qinghai Ji Weiyan Liu Ning Qu Ning Qu |
| author_sort | Hui He |
| collection | DOAJ |
| description | IntroductionAdvanced papillary thyroid cancer (PTC) has a poor prognosis, 60~70% of which become radio iodine refractory (RAI-R), but the molecular markers that assess PTC progress to advanced PTC remain unclear. Meanwhile, current targeted therapies are badly effective due to drug resistance and adverse side effects. Ligand-receptor pairs (L/R pairs) play an important role in the interactions between tumor cells and other cells in the tumor microenvironment (TME). Nowadays, therapies targeting ligand-receptor pairs in the TME are advancing rapidly in the treatment of advanced cancers. However, therapies targeting L/R pairs applied to advanced PTC remains challenging because of limited knowledge about L/R pairs in PTC.MethodsWe screened the critical L/R pair: CADM1-CADM1 using 65311 single-cell RNA sequencing (scRNA-seq) samples from 7 patients in different stage of PTC and bulk RNA-seq datasets containing data from 487 tumor samples and 58 para-carcinoma samples. Moreover, the expression levels of CADM1-CADM1 was assessed by quantitative real time polymerase chain reaction (qRT-PCR) and the function was analyzed using Transwell immigration assay.ResultsWe found that CADM1_CADM1 could be regarded as a biomarker representing a good prognosis of PTC. In addition, the high expression of CADM1_CADM1 can strongly increase the sensitivity of many targeted drugs, which can alleviate drug resistance. And the results of qRT-PCR showed us that the expression of CADM1_CADM1 in PTC was down-regulated and overexpression of CADM1 could suppresses tumor cell invasion migration.ConclusionOur study identified that CADM1_CADM1 played an essential role in the progression of PTC for the first time and our findings provide a new potential prognostic and therapeutic ligand-receptor pair for advanced PTC. |
| first_indexed | 2024-04-12T06:20:38Z |
| format | Article |
| id | doaj.art-924b2a358a9445beac3c7f055e4b80d3 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-12T06:20:38Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-924b2a358a9445beac3c7f055e4b80d32022-12-22T03:44:21ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-11-011310.3389/fendo.2022.969914969914Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq dataHui He0Hui He1Hui He2Shan Cong3Yu Wang4Yu Wang5Qinghai Ji6Qinghai Ji7Weiyan Liu8Ning Qu9Ning Qu10Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Laparoscopic Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Laparoscopic Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of General Surgery, Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaIntroductionAdvanced papillary thyroid cancer (PTC) has a poor prognosis, 60~70% of which become radio iodine refractory (RAI-R), but the molecular markers that assess PTC progress to advanced PTC remain unclear. Meanwhile, current targeted therapies are badly effective due to drug resistance and adverse side effects. Ligand-receptor pairs (L/R pairs) play an important role in the interactions between tumor cells and other cells in the tumor microenvironment (TME). Nowadays, therapies targeting ligand-receptor pairs in the TME are advancing rapidly in the treatment of advanced cancers. However, therapies targeting L/R pairs applied to advanced PTC remains challenging because of limited knowledge about L/R pairs in PTC.MethodsWe screened the critical L/R pair: CADM1-CADM1 using 65311 single-cell RNA sequencing (scRNA-seq) samples from 7 patients in different stage of PTC and bulk RNA-seq datasets containing data from 487 tumor samples and 58 para-carcinoma samples. Moreover, the expression levels of CADM1-CADM1 was assessed by quantitative real time polymerase chain reaction (qRT-PCR) and the function was analyzed using Transwell immigration assay.ResultsWe found that CADM1_CADM1 could be regarded as a biomarker representing a good prognosis of PTC. In addition, the high expression of CADM1_CADM1 can strongly increase the sensitivity of many targeted drugs, which can alleviate drug resistance. And the results of qRT-PCR showed us that the expression of CADM1_CADM1 in PTC was down-regulated and overexpression of CADM1 could suppresses tumor cell invasion migration.ConclusionOur study identified that CADM1_CADM1 played an essential role in the progression of PTC for the first time and our findings provide a new potential prognostic and therapeutic ligand-receptor pair for advanced PTC.https://www.frontiersin.org/articles/10.3389/fendo.2022.969914/fulladvanced PTCligand-receptor pairCADM1_CADM1targeted therapyprognostic biomarker |
| spellingShingle | Hui He Hui He Hui He Shan Cong Yu Wang Yu Wang Qinghai Ji Qinghai Ji Weiyan Liu Ning Qu Ning Qu Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data Frontiers in Endocrinology advanced PTC ligand-receptor pair CADM1_CADM1 targeted therapy prognostic biomarker |
| title | Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data |
| title_full | Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data |
| title_fullStr | Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data |
| title_full_unstemmed | Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data |
| title_short | Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data |
| title_sort | analysis of the key ligand receptor cadm1 cadm1 in the regulation of thyroid cancer based on scrna seq and bulk rna seq data |
| topic | advanced PTC ligand-receptor pair CADM1_CADM1 targeted therapy prognostic biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.969914/full |
| work_keys_str_mv | AT huihe analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT huihe analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT huihe analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT shancong analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT yuwang analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT yuwang analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT qinghaiji analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT qinghaiji analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT weiyanliu analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT ningqu analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata AT ningqu analysisofthekeyligandreceptorcadm1cadm1intheregulationofthyroidcancerbasedonscrnaseqandbulkrnaseqdata |